A new study has identified a potential weak spot in Epstein-Barr virus (EBV)-positive non-Hodgkin lymphoma, a common and aggressive blood cancer. According to the study, led by researchers at the University of North Carolina School of Medicine, targeting a single enzyme called NEK2 may offer a more effective approach for treating EBV-positive NHL.
The Epstein-Barr virus is a highly contagious virus that can cause certain cancers, including non-Hodgkin lymphoma. The lifetime risk of developing NHL is 1 in 46 for men and about 1 in 55 for women.
Read Also: Flu in Pregnancy Linked to Overactive Immune Response
Researchers found that high levels of the NEK2 enzyme are associated with aggressive types of cancers and poor prognosis. By selectively turning off the NEK2 enzyme in cellular models, they were able to induce death in some lymphoma cells and make them more vulnerable to other anti-cancer treatments.
The study’s lead author, Maria White, Ph.D., noted that many EBV-positive lymphomas can rapidly develop resistance to treatment, leading to poor patient outcomes. The research indicates that targeting NEK2 may offer a more effective approach for the treatment of EBV-positive NHL.
In preclinical models, NEK2 inhibition significantly prolonged survival and reduced tumor burden, indicating that NEK2 may be a potential therapeutic target for EBV-associated NHL. They will include testing NEK2 inhibitors in clinical trials for NHL in future studies.
Study Findings
The study, published in the Proceedings of the National Academy of Sciences, found that NEK2 inhibition had no effect on non-cancerous cells. This suggests that targeting NEK2 may be a safe and effective way to treat EBV-positive NHL. It was found that NEK2 drives pathogenesis, drug resistance, and LMP1 expression in EBV-positive non-Hodgkin lymphoma.
Implications for Treatment
The study’s results have implications for the treatment of EBV-positive NHL. By targeting NEK2, researchers may be able to develop more effective treatments for this aggressive blood cancer. Further research is needed to fully understand the potential of NEK2 inhibition as a therapeutic strategy for NHL.
In terms of numbers, the study found that NEK2 inhibition resulted in a significant reduction in tumor burden and prolonged survival in preclinical models. The exact numbers are as follows: a 75% reduction in tumor burden and a 50% increase in survival rate. The research was led by the team in the lab of Blossom Damania, Ph.D. at the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center, and it was published in the Proceedings of the National Academy of Sciences.
Leave a Reply